跳至主要内容
临床试验/NCT02125825
NCT02125825已完成不适用

Kinesia-D Phase II In-Clinic Continuous Assessment Study

Great Lakes NeuroTechnologies Inc.2 个研究点 分布在 1 个国家目标入组 14 人开始时间: 2014年7月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
14
试验地点
2
主要终点
Correlation between motion sensor features and clinician-rated dyskinesia severity

研究概览

简要总结

The objective is to assess a compact, portable, wireless movement disorder system with continuous monitoring capabilities to detect and quantify the severity of levodopa-induced dyskinesia in Parkinson's disease.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Cross Sectional

入排标准

年龄范围
21 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosis of idiopathic Parkinson's disease
  • Clinical history of levodopa-induced dyskinesia
  • 21 Years of age or older
  • Stage 2 - 4 OFF-medication on the Hoehn and Yahr scale

排除标准

  • Dementia (determined by a neuropsychological assessment)
  • Severe tremor unaffected by levodopa

结局指标

主要结局

Correlation between motion sensor features and clinician-rated dyskinesia severity

时间窗: All data will be collected within a single session not to exceed 3 hours

Motor function (movement speed and magnitude measured with a motion sensor) will be collected for a period of 2 hours after taking normally prescribed dose of levodopa.

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验